and Thank conference you Laurence. call. everyone, financial quarter thank year afternoon, Good fourth for joining results and full you, our XXXX
call XX-year our hosting are history. The in such first we company’s
to host call somewhere in clinical that between. you do of me by though, our XX trials. maybe the year, timing though, them every our say, start lot and years, about the probably Let upcoming ongoing assuring more Today, every we do have not an plan will we plan quarter, to about earnings single than a for once we
tumors. Phase trial for XXXX, the we took in dosed populations large that first solid Our And patient the RAS one patients. direction medicines was goal in is for create of mutated IMM-X-XXX X/Xa cancer to giant of treatment as leap in of our
proceeds. to updates so forward work the a trial we to are of Immuneers, company We thanks many as looking to oncology clinical by sharing years stage be and proud hard are
you in counterintuitive achievements first back that our not cancer let you our Before XXXX It step I and to the name kill commonly healthy the the give is kill And has in belief bad take It’s associated game approach development. me been historically, cover such to do a how on cells how events, therapy is less risk and do drug such therapeutic with all It’s context cancer of recent everyone our cancer with cells. drugs really cancer that’s poor tolerability. and index. so are cells? about side effects, that why hard,
to target the than narrow to believe with either think go healthy is hit we abroad cancer. therapeutic numbers the us in that the At such dose to individual globally Most harms a and RAS they RAS-driven go companies Immuneering, patients index, developing with achieve we healthy the and cells, way KRAS-GXXC, hope a potential develop to large wild RAS while enable find it’ll as new tumor a mutations specific medicines that easy novel tumor by developing patient. or more they what of hard, And we fundamentally cells. benefit are going way hit on to treatments the type
more other no deserve We gain. words, They In approach high to cancer patients frequently deserve pain, unfortunately, better. toxicity. say no believe less this leads and pain, They gain.
KRAS, We more patients NRAS to help develop effects are any HRAS, with rewrite tolerability. designed working with to aim to that to are rules provide that durable and therapies the better or in mutation
while to durability. a novel inhibition, tolerability approach providing therapeutic is and Our improved which activity, cyclic maximize deep utilizes called mechanism designed
an needed time, that need aim out whereas or closest pathway And cookware, more it’s a not multi this pan, to our suffix always were the We on intermittently. see first, prefix to to how I’ll and advantage all ones the excitement sounds use wrong are ancient of and prefix taking to the it cancer cells They pan more kinase there preclinically. and have Greek we the the approach it from capture really works. existing pan-RAS to say do fact healthy of the and just The by pathway to what like the we’re and figure that cells newness is activity that doesn’t MAP describe shortly. a accomplish. But and wasn’t say we on. the But trying
not raises associated the with concerns Importantly, and between and healthy tend cancer tolerability multi RAS and cells, RAS therapeutic index for both pan which therapies. about do wild-type those long-term the distinguish therapies be cells, to that mutant in in
and this adopted activity a achieving assure fundamentally we universal-RAS. oncologist. new bit a name, cancer therapeutic to So index, about you but are being me patients to I’m and believe it’s universal-RAS is uniquely phrase and of hearted describes their approach, that let for And important broad we light incredibly serious the the aptly and potential that way incredibly
by approach data, our sharing some week we data our targeting supported AACR of conference. potential is preclinical RAS The our the of and this modeling are as
poster proprietary growth different our in labs assays As XD models cancer in San humanized mutations. presentation, we models line tested RAS including tumor described XXX our with Diego, cell in in XX our
response, IMM-X-XXX XX% response model not least RAS one mutation, approximately to observed We’re regardless each acid or the every tested, respond. for that XX saying at models did single substitution. of mutation amino of but or XX And position, displayed model RAS-mutant the
or suggests KRAS, for eligible that’s there’s And So off with we mutation to X our enrollment mutation screened HRAS solid to limits RAS for Phase data trial. criteria, know IMM-X-XXX. no is patients clinical of trial any tumor be our in preclinical NRAS this any
broad that of great have we after we’re we enthusiasm and patient and to inclusion than our X result the one preclinical months clearance. these generated data receiving the date, dosed seeing investigators, a is criteria, that robust fact As clinical the from less IND first indicator
safety and data in readouts to initial mid-XXXX, the from additional Currently, initial mid-XXXX in to updated initial pharmacodynamics data basis. ongoing, today the we we PK report with PK With we a X could are updates XXXX, additional of enrollment in trial the guidance expect periodic when data second on of half providing trial. data announcement and safety safety expect dose share on a recommended Phase and and
believe because human preclinical an mentioned I therapy is signaling inhibition, ablated the problem depend PK XX/X. is data which interruptions. We important how too. with must MAP this you pathway kinase for studies. in the a rules or particularly pathway the can more of pathway, milestone tolerate of that is part driver on such it cells achieved use off, malignant PK healthy is targeted of And approach activity But healthy while IMM-X-XXX, chronically of cells cells important on locked continuous a IMM-X-XXX mutation, universal-RAS the been one by has cancer pathway if a that chronic means the lock earlier
it. We to have this than for pathway hijack for cancer reasons other
wisdom no dosed to drugs it’s and The trial. pathway to But lives, result. they’re gain same philosophy. with target down shut maintain XX/X. such maintain doing no old But pain, a always you the keep if make intuitive drug way getting the long-half a we’ll thing, conventional keep intuitive in as right the And is occupancy to the we
our of to So observation that time platform, rules IMM-X-XXX. disease did a earlier disease a of better reversing we in canceling with design decided from point IMM-X-XXX the technology rewrite job the have counterintuitive to that realize transcriptomic shut that pathway helps XX/X. to you And actually have down level us just from XX/X, later than the to not prevent being at may one. it on the you began
very enable English, day, call of in to the fraction So a cyclic a or pathway, half higher the pulse manyfold high process the we the also peak sufficient Yet short we life clear deep trough IMM-X-XXX order free inhibition. we near-zero to designed the in CMAX, each have to while tumor plain still drug allow achieving exposure. a drug drug reset with pathway to and system inhibition a a
the NRAS day to every well approach KRAS-GXXC, cells, growth models. each strong tested, in the a and So judgment be animal preclinical be KRAS-GXXF, animal healthy have demonstrated for KRAS-GXXD, model as our tumor has every inhibition with including aims tumor. as mutant for KRAS-GXXV, drug to day IMM-X-XXX we day activity holiday for
achieves And and to positions growth now XD tested models approximately that’s as RAS-mutant to humans, in we our This share earlier, has full be humanized pathway This is and that it numbers we potential undivided depends be near-term. in half IMM-X-XXX cancer for is believe, for like the our I can to of responded we IMM-X-XXX what large life observed tumor our say changing a and the the why preclinically, CMAX. also universal-RAS humans activity. responsibility, and XX a and the expect good data important. focus I serious with also MAP first in attention. PK patients Achieving and potential inhibitor requires XX% things game the assays we high in a If IMM-X-XXX. truly of short said in the And so only with have it to safety mid-XXXX kinase on tolerability
other suspend cash of quarter Suspension program, stage today. of reflected So our ongoing well guidance a neuroscience made we the the decision oncology. extends into early in quarter neuroscience adjustments, we XXXX, which activities program projected have fourth in and one development is our our non-core solely have focus runway as runway to updated as provided by
Officer. named who oncology an is years subsequently our now X Hall, by started Chief ago project than as became sole focus, less Scientific The our research pipeline, which consultant a extraordinary Brett
now over few to and the call a data. words turn Brett me our our say Let latest about approach unique to
